225 (19) 119 (17) 252 (19) IV 1084 (10) 158 (13) 64 (9) 122 (9) Unknown 1618 (14) 175 (15) 81 (11) 172 (13) Differentiation <0.01
Well-differentiated 1115 (10) 177 (10) 71 (10) 137 ( Poorly/undifferentiated 3294 (28) 302 (25) 201 (27) 401 (29) Unknown 2594 (23) 309 (26) 145 (20) 265 (19) Facility type <0.01
Community CP 698 (6) 72 (6) 38 ( (11) 97 (14) 227 (17) No insurance 218 (2) 57 (5) 37 (5) 185 (14) Median household income for each patient's area of residence <0.01 <$38 000 1609 (14) 511 ( [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] 13 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 13 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] 13 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Patients who have resectable tumors usually undergo pancreaticoduodenectomy, with some centers advocating for adjuvant therapy. 12, 13 The natural history and epidemiology of this disease have been described only in small single-institution studies and older population-level reports performed more than a decade ago. 8, 9, 11, [14] [15] [16] [17] [18] [19] In addition, little information exists about the racial and ethnic variation in the clinical presentation, treatment, and outcomes of this malignancy. 8 In this study, we used information from the National Cancer 
| MATERIALS AND METHODS

| Study design
| Patient selection
We identified patients with ampullary cancer using the International 
| Statistical analysis
We used SPSS (version 21.0) to perform all statistical analysis.
Continuous variables were presented as medians with interquartile ranges and categorical variables as counts with percentages. We used Surgery + chemotherapy 1432 (13) 159 (14) 125 (18) 204 (16) Surgery + radiation 66 (0.6) 12 (1) 7 (1) 13 (1) Surgery + chemo + radiation 1670 (15) 177 (16) 96 (14) 203 (16) Chemo alone 644 (6) 96 (8) 43 (6) 73 (6) Radiation alone 129 (1) 15 (1) 8 (1) 7 (0.5)
Chemo + radiation 326 (3) 44 (4) 13 (2) 26 (2) 30-day readmission 629 (8. 3 | RESULTS
| Patient characteristics
Patient-and tumor-related characteristics are summarized in Table 1 .
We excluded 1228 patients who did not have race/ethnicity information or were classified as "other" and 892 patients for non- Table S1 ). The proportion of White patients decreased from 81% in 2004 to 74% in 2014, while Blacks increased from 7% to 10%, Asians from 4% to 6%, and Hispanics from 8% to 10% during the same period.
Whites presented at an older median age (72 years) than the other groups (Asians at 67 years, Blacks and Hispanics at 65 years; P < 0.01)
but Blacks tended to have more comorbidities on presentation (P < 0.01) and were diagnosed more often with metastatic disease (13%) than Whites (10%), Hispanics (9%), and Asians (9%, P < 0.01).
Whites were less likely to be uninsured (2%, P < 0.01) compared to Asians, Blacks (5% for both), and Hispanics (14%). Blacks lived in areas with lowest median household income, with 43% residing in areas where median income was less than $38 000 annually compared to 27% for Hispanics, 14% for Whites, and 12% for Asians (P < 0.01).
| Treatment utilization
There was a significant difference in treatment utilization with
Blacks having the highest rate of non-treatment (26%), followed by Whites (24%), Hispanics (21%), and Asians (18%, P < .01). Significantly, Blacks were least likely to have a surgical intervention overall (61%) as compared to Whites (66%), Hispanics (71%), and Asians (73%, P < .01). There were no differences in 30-day readmission or 90-day mortality between the four groups.
To determine if there were any stage-specific differences in treatment use, we evaluated treatment patterns in a stage-specific manner and summarized the results in Supplementary Table S2 . We found that Blacks were more likely to have no treatment for stage I disease (27%) compared to Whites (23%), Hispanics (20%), and (Table 2) . After adjusting for all these factors, Black patients still had less treatment utilization than Whites (odds ratio, 0.76; 95% CI, 0.64-0.90).
| Survival analysis
Short-to long-term survival data are presented in Figure 1 . Blacks had the lowest median overall survival at 18.9 months (95% CI, 
| DISCUSSION
This is a contemporary hospital-based analysis of ampullary cancer outcomes. We found significant differences in presentation, treatment utilization, and outcomes across different races and ethnicities. Most strikingly, we found that after controlling for other prognostic factors, Blacks had the worst overall survival, while Asians and Hispanics had the longest survival. Our findings confirmed that race and ethnicity are associated with differential outcomes in ampullary cancer patients.
Furthermore, this study provides a comprehensive updated survival analysis stratified by stage, race, and ethnicity, which can be used when counseling patients with this rare disease.
Cancer outcomes disparity due to race and ethnicity have been attributed to interrelated effects of socioeconomic status, access to care, and inherent tumor biology. 1, 6, 7 It is unclear to what magnitude race and ethnicity are surrogate markers for socioeconomic factors, such as education, insurance, occupation, living conditions, and behavioral risk factors (smoking, obesity, etc.) or whether there are inherent biologic differences between patients of different races and ethnicities. While some authors have concluded that non-cancer deaths, presentation, and treatment drive the differential outcomes seen in cancer patients of different races and ethnicities, 21 other studies have shown that race and ethnicity are associated with biological differences, such as chemotherapy response rate. 4, 5 In this study, we found that Blacks tended to have lower socioeconomic status and lower treatment utilization that may partially explain the poor outcomes and higher rate of metastasis on presentation. Thus, improving access to care for Black patients may decrease the gap in outcomes. However, we also found that after adjusting for treatment utilization, being Black was still associated with worse survival, which
indicates that other factors such as biology may be responsible for the difference.
Another striking finding in our study is that Asian and Hispanic 24 Future studies with detailed disease specific survival will be necessary to further clarify this point. We also could not determine the incidence of ampullary by race and ethnicity as we could not ascertain the total number of patients studied. Finally, the NCDB lacked disease-specific variables, such as intestinal or pancreaticobiliary histology, which have been shown to be prognostic in ampullary cancer. [25] [26] [27] [28] [29] [30] However, a previous study by
Carter et al. showed that there was no association between race/ ethnicity and histology type. 29 Despite these limitations, this study highlights differences in survival between White, Black, Asian, and Hispanic patients with ampullary cancer. It showed that Black patients had the worst survival, while Asians and Hispanics had the best outcomes even after adjusting for stage, treatment utilization, and socioeconomic status. There is an urgent need to understand the extent that socioeconomic factors versus inherent tumor biology determine cancer outcome disparities associated with race and ethnicity. Identifying the principal drivers of these differences in survival will define the most effective strategies for reducing the survival gap between different racial and ethnic groups.
